A phase II study of oral S‐1 with concurrent radiotherapy followed by chemotherapy with S‐1 alone for locally advanced pancreatic cancer

Shinchi, Hiroyuki; Maemura, Kosei; Mataki, Yuko; Kurahara, Hiroshi; Shimada, Masahiko; Ueno, S.; Hiraki, Yoshiyuki; Nakajo, Masayuki; Takao, Sonshin

doi:10.1007/s00534-011-0400-y

Cited by 45 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MST of BR-PDAC patients with an NLR of >3 (n = 12) or a PLR of >225 (n = 8) was 10.2 months in each group. In recent phase II studies, the MST of patients with locally advanced UR-PDAC who received non-surgical treatment has been reported to be 13-17 months [32][33][34][35]. It is obviously not beneficial for these patients to undergo an "upfront" surgical approach.…”

Section: Discussionmentioning

confidence: 99%

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The median survival time of the patients with locally advanced pancreatic cancers that received chemoradiotherapy or radiotherapy alone or chemotherapy alone was found to be between 5.7-16.8 in a previous randomized controlled study [8][9][10][12][13][14][15][16]. In particular, the results of the median survival time with chemoradiotherapy with TS-1 had been 11-16.8 months [17][18][19][20][21][22]. Our study included 12 patients with TS-1 and a median survival time of 10.8 months, which is slightly inferior compared to previous reports.…”

Section: Discussionmentioning

confidence: 90%

Clinical Results of Radiotherapy for Locally Advanced Stage III Pancreatic Cancer: A Single Institutional Experience

Hatayama¹,

Aoki²,

Kawaguchi³

et al. 2018

Int J Oncol Res

View full text Add to dashboard Cite

“…S-1 is an oral 5-FU prodrug. Several phase II studies of S-1 cCRT have demonstrated an acceptable toxicity profile and promising efficacy with a response rate of 24%-41% and median survival of 12.9-16.8 mouths (21)(22)(23)(24). Nowadays, it's widely used in Asia.…”

Section: Discussionmentioning

confidence: 99%

Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer

Zhou

Fan

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Object: To evaluate the efficacy and tolerability of consolidative chemoradiotherapy (cCRT) after induced chemotherapy (iCT) for locally advanced pancreatic cancer (LAPC). Patients and methods: Patients with LAPC were enrolled from January 2013 to November 2018. In stage one, all patients received iCT. Those without distant metastasis proceeded to stage two, received 50.4 Gy cCRT with S-1 as radiosensitizer. Efficacy and tolerability were evaluated in all patients. Results: Sixty-five patients enrolled into this study and accepted iCT. Eleven (16.9%) patients got early progressions or declined general condition, 1 (1.5%) patient quit the trial after one cycle of iCT. These 12 patients didn't receive cCRT. The remaining 53 (81.5%) patients received cCRT. After cCRT, 4 of 53 (7.5%) patients accepted radical resection. The treatment was well-tolerated. In stage one, neutropenia and thrombocytopenia were the most frequent toxicities, the severe toxicity (grade 3 and 4) were 26.2 and 20.0%, respectively. In stage two, fatigue (45.3%) and nausea (41.5%) were the most frequent toxic effects but most were mild. The median overall survival (OS) of whole group was 18.1 months [95% CI, 15.11-21.03 months]. The OS of patients with early progression and patients accepted cCRT were 7.6 months [95% CI, 5.22-10.02 months] and 19.5 months [95% CI, 18.08-20.95 months], respectively (P < 0.001). The PFS of the 53 patients was 10.3 months [95% CI, 8.54-11.96 months] and survival rates at 1-and 2-years were 84.8 and 24.3%, respectively. Conclusion: The current results indicate that iCT is a useful screening method to selecting LAPC patients with less-aggressive biological behavior. cCRT after iCT in patients with LAPC is an optimal treatment. The prognosis of patients who received complete treatment is significantly improved.

show abstract

A phase II study of oral S‐1 with concurrent radiotherapy followed by chemotherapy with S‐1 alone for locally advanced pancreatic cancer

Abstract: Combination therapy with S-1 and radiation in patients with locally advanced and unresectable pancreatic cancer is considered a promising, well-tolerated regimen that can be recommended as an effective treatment for locally advanced pancreatic cancer.

Cited by 45 publications

References 27 publications

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios

Clinical Results of Radiotherapy for Locally Advanced Stage III Pancreatic Cancer: A Single Institutional Experience

Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer

Contact Info

Product

Resources

About